MX2019013157A - Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. - Google Patents
Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos.Info
- Publication number
- MX2019013157A MX2019013157A MX2019013157A MX2019013157A MX2019013157A MX 2019013157 A MX2019013157 A MX 2019013157A MX 2019013157 A MX2019013157 A MX 2019013157A MX 2019013157 A MX2019013157 A MX 2019013157A MX 2019013157 A MX2019013157 A MX 2019013157A
- Authority
- MX
- Mexico
- Prior art keywords
- fragment
- sequence
- pharmaceutical compositions
- terminal
- manf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona una secuencia de un fragmento de CDNF C-terminal, o una secuencia que tiene por lo menos 90 % de homología con dicha secuencia. El fragmento CDNF C-terminal protege a las neuronas, neuronas motrices y neuronas dopaminérgicas con RE estresado, y el fragmento es capaz de penetrar la membrana celular neuronal y también la barrera hematoencefálica. La presente invención proporciona, además, dicho fragmento y composiciones farmacéuticas que comprenden dicho fragmento para usarse en el tratamiento de enfermedades y trastornos degenerativos que incluyen enfermedades del sistema nervioso central, diabetes y trastornos retinianos. La presente invención también proporciona una secuencia de un fragmento de MANF C-terminal, o una secuencia que tiene por lo menos 90 % de homología con dicha secuencia, y composiciones farmacéuticas que comprenden dicho fragmento de MANF para usarse en el tratamiento de enfermedades y trastornos degenerativos que incluyen enfermedades del sistema nervioso central, diabetes y trastornos retinianos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20175392 | 2017-05-04 | ||
PCT/FI2018/050332 WO2018202957A1 (en) | 2017-05-04 | 2018-05-04 | C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019013157A true MX2019013157A (es) | 2020-08-03 |
Family
ID=62218004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019013157A MX2019013157A (es) | 2017-05-04 | 2018-05-04 | Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200071372A1 (es) |
EP (1) | EP3619227A1 (es) |
JP (1) | JP7384672B2 (es) |
KR (1) | KR20200003889A (es) |
CN (1) | CN110831960A (es) |
AU (1) | AU2018263087B2 (es) |
BR (1) | BR112019023116A2 (es) |
CA (1) | CA3062241A1 (es) |
MX (1) | MX2019013157A (es) |
RU (1) | RU2019136495A (es) |
SG (1) | SG11201910183SA (es) |
WO (1) | WO2018202957A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020010301A (es) * | 2018-03-29 | 2020-10-20 | Helsingin Yliopisto | Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. |
EP3838345A1 (en) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Macrocyclic peptides |
EP3838912A1 (en) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Retro-inverso peptides |
WO2021160938A1 (en) | 2020-02-13 | 2021-08-19 | Herantis Pharma Oyj | Systemic administration of a pharmaceutical composition comprising cdnf or manf polypeptide for use in the treatment of reperfusion injury |
CN117018231B (zh) * | 2023-08-16 | 2024-05-10 | 科辉智药(深圳)新药研究中心有限公司 | 用于治疗神经病变的基因疗法及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
CA2441327A1 (en) * | 2001-03-30 | 2002-10-10 | Geneprot, Inc. | Human arginine-rich protein-related compositions |
JP5236488B2 (ja) | 2005-12-14 | 2013-07-17 | ハーモ ファーマ エルテーデー. | 新規な神経栄養因子タンパク質およびその用途 |
FI20080326A0 (fi) * | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
FI20115870A0 (fi) | 2011-09-05 | 2011-09-05 | Urmas Arumaee | Neuroprotektiiviset soluihin tunkeutuvat peptidit |
WO2014191630A2 (en) | 2013-05-28 | 2014-12-04 | Helsingin Yliopisto | Non-human animal model encoding a non-functional manf gene |
WO2015149005A1 (en) * | 2014-03-28 | 2015-10-01 | Buck Institute For Research On Aging | Methods and compositions for modulating the immune system |
WO2016057579A1 (en) | 2014-10-06 | 2016-04-14 | Amarantus Bioscience Holdings, Inc. | Methods and compositions for treating retinal disorders |
-
2018
- 2018-05-04 EP EP18726203.5A patent/EP3619227A1/en active Pending
- 2018-05-04 WO PCT/FI2018/050332 patent/WO2018202957A1/en unknown
- 2018-05-04 AU AU2018263087A patent/AU2018263087B2/en not_active Ceased
- 2018-05-04 SG SG11201910183S patent/SG11201910183SA/en unknown
- 2018-05-04 JP JP2019560290A patent/JP7384672B2/ja active Active
- 2018-05-04 CN CN201880044874.3A patent/CN110831960A/zh active Pending
- 2018-05-04 CA CA3062241A patent/CA3062241A1/en active Pending
- 2018-05-04 US US16/610,532 patent/US20200071372A1/en active Pending
- 2018-05-04 BR BR112019023116-1A patent/BR112019023116A2/pt not_active IP Right Cessation
- 2018-05-04 MX MX2019013157A patent/MX2019013157A/es unknown
- 2018-05-04 RU RU2019136495A patent/RU2019136495A/ru unknown
- 2018-05-04 KR KR1020197035908A patent/KR20200003889A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
CA3062241A1 (en) | 2018-11-08 |
SG11201910183SA (en) | 2019-11-28 |
JP2020518261A (ja) | 2020-06-25 |
BR112019023116A2 (pt) | 2020-07-28 |
WO2018202957A1 (en) | 2018-11-08 |
AU2018263087A1 (en) | 2019-11-28 |
AU2018263087B2 (en) | 2021-12-16 |
US20200071372A1 (en) | 2020-03-05 |
EP3619227A1 (en) | 2020-03-11 |
CN110831960A (zh) | 2020-02-21 |
KR20200003889A (ko) | 2020-01-10 |
RU2019136495A (ru) | 2021-06-04 |
JP7384672B2 (ja) | 2023-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019013157A (es) | Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. | |
MX2018010693A (es) | Compuestos biciclicos para diagnostico y terapia. | |
BR112019010646A2 (pt) | métodos de tratamento de condições inflamatórias | |
BR112012020953A2 (pt) | produto, uso do mesmo, metodo para prevencao e/ou tratamento de fibrose corneana ou opacidade corneana e composicao farmaceutica oftalmica | |
WO2017062456A3 (en) | Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof | |
PH12020500573A1 (en) | 1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer`s disease | |
BR112017014332A2 (pt) | métodos de tratamento de doenças retinianas | |
AU2016249140A8 (en) | Anti-PACAP antibodies and uses thereof | |
MX2009012919A (es) | Tratamiento terapeutico para el sindrome metabolico, diabetes tipo 2, obesidad, o prediabetes. | |
EP3712264A8 (en) | Cystathionine beta-synthase enzyme for treatment of homocystinuria | |
MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
MX2017000378A (es) | ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS. | |
MX2020010301A (es) | Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. | |
BR112022013843A2 (pt) | Método de diferenciação de células neurais e composições relacionadas e métodos de uso | |
CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
MX2021000954A (es) | Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales. | |
MX2020001855A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides. | |
EP3937937A4 (en) | TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH MITOCHONDRIA, INCLUDING THEIR SYMPTOMS USING PRIDOPIDINE | |
MX2015008555A (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
WO2014053110A3 (de) | Peptide zur behandlung und frühdiagnose von morbus alzheimer und anderer tauopathien | |
BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
BR112017008734A2 (pt) | acelerador de produção de proteína tau e agente preventivo ou terapêutico e composição alimentícia preventiva ou terapêutica para doenças causadas por deficiência de proteína tau | |
EP3639854A4 (en) | MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF | |
BR112018001267A2 (pt) | método de diagnosticar asma, uso de um antagonista do receptor de crth2, produto de fármaco, e, kit | |
MX2021009326A (es) | Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo. |